TOI
The Oncology·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TOI
The Oncology Institute, Inc.
A biotechnology company that develops and commercializes innovative cancer therapies and diagnostics
Healthcare Providers and Services
11/01/2019
06/04/2020
NASDAQ Stock Exchange
825
12-31
Common stock
18000 Studebaker Rd, Suite 800, Cerritos, California 90703
--
The Oncology Institute, Inc., a Delaware corporation incorporated on November 1, 2019. The company is a leading value-based oncology company that manages community-based oncology practices serving patients in 76 clinics in 15 markets and 5 states in the United States. The company's community-based oncology clinics are staffed with 112 oncologists and advanced clinic providers. Of these clinics, 62 clinics are staffed with 101 medical personnel who are employed by their affiliated doctor-owned professional companies called "TOI PCs. ". The clinics managed by the company provide a range of oncology medical services, including physician services, in-house infusion and pharmacy, clinical trial services, radiology, innovative programs such as outpatient blood product transfusion, and round-the-clock patient support.
Earnings Call
Q2/2025
Estimate EPS--
Actual EPS-0.15
Estimate Revenue113.17M
Actual Revenue119.80M
The Oncology Institute's Q2 2025: Navigating Contradictions in Drug Pricing, Revenue Growth, and Patient Volume
Aug 13,2025 08:33
Earnings Decrypt
Earnings Decrypt
Q1/2025
Estimate EPS--
Actual EPS-0.21
Estimate Revenue--
Actual Revenue104.41M
Examining Contradictions: Revenue Growth, Contract Impact, and Expense Management in Latest Earnings Call
May 20,2025 09:41
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
TOI has released its 2025 Q3 earnings. EPS was reported at -0.14, versus the expected -0.11, missing expectations. The chart below visualizes how TOI has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TOI has released its 2025 Q3 earnings report, with revenue of 136.56M, reflecting a YoY change of 36.70%, and net profit of -16.50M, showing a YoY change of -2.43%. The Sankey diagram below clearly presents TOI's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
